CAJ | 학술논문

背景与目的：雌激素信号传导在非小细胞肺癌(non-small cell lung cancer，NSCLC)中存在争议，体外实验发现，雌激素受体(estrogen receptor，ER)ERβ与肺内组织的异常增生相关，ERβ在正常组织和肺癌组织中的表达结果不同。本研究旨在探讨ERα和ERβ在非吸烟NSCLC患者中的表达与临床病理特征和生存期的关系。方法：收集有组织学病理诊断的144例非吸烟的NSCLC组织及其临床资料，免疫组化方法检测ERα和ERβ表达状况并分析与临床特点和生存期的关系。结果：ERα阳性表达率为7.6%，仅在腺癌中表达， ERα表达状态与生存期无关。ERβ表达率为52.1%，Ⅰ、Ⅱ期患者的表达显著高于Ⅲ、Ⅳ期，差异有统计学意义(P=0.020)。ERβ表达阳性和阴性的中位生存期(median survival time，MST)分别为43和38个月，差异有统计学意义(P=0.028)，ERβ表达阳性和阴性的女性MST分别为45和37个月，差异有统计学意义(P=0.033)。在腺癌中ERβ阳性和阴性表达的MST分别为46和38个月，差异有统计学意义(P=0.021)。结论：ERβ在早期非吸烟NSCLC中表达增高，是女性、腺癌生存期良好的标志。
배경여목적：자격소신호전도재비소세포폐암(non-small cell lung cancer，NSCLC)중존재쟁의，체외실험발현，자격소수체(estrogen receptor，ER)ERβ여폐내조직적이상증생상관，ERβ재정상조직화폐암조직중적표체결과불동。본연구지재탐토ERα화ERβ재비흡연NSCLC환자중적표체여림상병리특정화생존기적관계。방법：수집유조직학병리진단적144례비흡연적NSCLC조직급기림상자료，면역조화방법검측ERα화ERβ표체상황병분석여림상특점화생존기적관계。결과：ERα양성표체솔위7.6%，부재선암중표체， ERα표체상태여생존기무관。ERβ표체솔위52.1%，Ⅰ、Ⅱ기환자적표체현저고우Ⅲ、Ⅳ기，차이유통계학의의(P=0.020)。ERβ표체양성화음성적중위생존기(median survival time，MST)분별위43화38개월，차이유통계학의의(P=0.028)，ERβ표체양성화음성적녀성MST분별위45화37개월，차이유통계학의의(P=0.033)。재선암중ERβ양성화음성표체적MST분별위46화38개월，차이유통계학의의(P=0.021)。결론：ERβ재조기비흡연NSCLC중표체증고，시녀성、선암생존기량호적표지。
Background and purpose:The involvement of estrogen signaling in lung cancer is controversial. But the findings showed that ERβ might play an important role in neoplastic lung biology. Several studies have evaluated expression of ERβin both normal and neoplastic human lung tissues with variable conclusions. We aimed to evaluate the expressive of estrogen receptors (ER)α,βin non-smoking non-small cell lung cancer (NSCLC) and investigate the relationships between the survival and expressions of ERα,β. Methods:Immunohistochemical assay was used to detect the expression ERαand ERβin 144 NSCLC patients, and analyzed the expressions status of ERα,βand survival. Results:The positive rate of ERαwas 7.6%, only in adenocarcinoma cancer. The positive rate of ERβwas 52.1%, and the expressions of stageⅠandⅡwas signiifcantly higher than that of stageⅢandⅣ(P=0.020). The median survival time (MST) of ERβpositive expression was better than that of negative expression (43 months vs 38 months, P=0.028). The MST of ERβpositive expression of female patients was better than that of negative expression (45 months vs 37 months, P=0.033). The MST of ERβpositive expression of adenocarcinoma were 46 months and better than negative 38 months (P=0.021). Conclusion:The expression of ERβwas signiifcantly higher in early-stage non-smoking NSCLC. It indicated that the positive expression of ERβwas related to the better MST, especially in female adenocarcinoma patients.